131I-mAbG250 localized specifically to G250 antigen-positive RCC and seems to have considerable potential as an imaging agent in RCC patients. 131I-mAbG250 uptake in the tumors, relative as well as absolute, are among the highest reported for tumor biopsies obtained 8 days after IV mAb administration. Based on the specific localization and high accumulation, mAb G250 may have therapeutic potential.
No takes yet. Share an insight, caveat, or question.
Oosterwijk et al. (1993) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: